Article
CMS payment model for cancer treatment offers new incentives for providers
July 14, 2024 · Authored by Georgia Green
The Centers for Medicare and Medicaid Services (CMS) announced on May 30, 2024, that it will offer a second opportunity to apply to the Enhancing oncology model (EOM) in July 2024. CMS also announced important refinements to the model’s policies designed to incentivize more providers to participate.
EOM is a voluntary payment model intended to better support patients undergoing cancer treatment and reduce Medicare fee-for-service (FFS) spending.
It’s important to understand the potential benefits and financial implications of the model to determine whether participation would be beneficial for your organization and prepare for compliance and reporting requirements.
Payment model design
In this model, participating oncology practices assume the financial and quality performance responsibility for a six-month episode of care surrounding chemotherapy administration to Medicare patients with common cancer types.
The model will begin July 2025 and run for five years through June 2030.
EOM builds on the Oncology Care Model, which ran from July 2016 to June 2022.
Per the model’s Fact sheet, EOM focuses on individuals receiving systemic cancer treatment for seven cancer types:
- Breast cancer
- Chronic leukemia
- Small intestine and colorectal cancer
- Lung cancer
- Lymphoma
- Multiple myeloma
- Prostate cancer
Participants in the model continue to receive FFS payments, and additionally receive the following two incentives designed to improve quality and reduce cost.
Monthly enhanced oncology services (MEOS) payment
Related sections
October 2025 Policy Pulse
The information provided here is of a general nature and is not intended to address the specific circumstances of any individual or entity. In specific circumstances, the services of a professional should be sought. Tax information, if any, contained in this communication was not intended or written to be used by any person for the purpose of avoiding penalties, nor should such information be construed as an opinion upon which any person may rely. The intended recipients of this communication and any attachments are not subject to any limitation on the disclosure of the tax treatment or tax structure of any transaction or matter that is the subject of this communication and any attachments.